Comparative effectiveness among BRAF plus MEK inhibitors for patients with BRAF V600-mutant melanoma☆

Background: Understanding of comparative efficacy of treatments can inform clinical decision-making. This study compared overall survival (OS) and progression-free survival (PFS) across patients with metastatic BRAFV600-mutant melanoma initiating encorafenib + binimetinib (ENCO + BINI), dabrafenib +...

Full description

Saved in:
Bibliographic Details
Main Authors: G.K. In, K. Chen, G. Sajeev, R. Simpson, S. Kalia, D. Christensen, D. Liu, N. Rezai, A. di Pietro, J. Signorovitch
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:ESMO Real World Data and Digital Oncology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2949820124000493
Tags: Add Tag
No Tags, Be the first to tag this record!